CureVac seeks Covid-19 shot approval in Switzerland
German drugmaker CureVac has submitted an application for the approval of its Covid-19 mRNA vaccine with Swiss drugs regulator Swissmedic. Until now Switzerland has approved three vaccines, two of which are being used.
Switzerland has already placed orders for five million doses of CureVac’s mRNA vaccine, which is similar to those from Moderna and Pfizer that are already being administered across the country.
The submission is part of a rolling review procedure to “evaluate the scientific data as soon as they become available”, Swissmedic said.
“CureVac can forward documentation on its vaccine candidate on an ongoing basis without having to await the final results of the clinical trials,” it said. However, it is unclear how long the review will take.
“The duration of the rolling review will depend on the completeness of the data submitted by CureVac and the results of the clinical trials, and cannot therefore be predicted,” Swissmedic said.
Swiss drugmaker Novartis has agreed to help make CureVac’s vaccine at a plant in neighbouring Austria.
AstraZeneca status
Although AstraZeneca was the first company to start the review process in Switzerland in early October for its vaccine, regulators have said they still don’t have enough information to approve the British company’s shot.
Swiss authorities have ordered nearly 36 million vaccine doses from Pfizer/BioNTech (6 million), Moderna (13.5 million), AstraZeneca (5.3 million), CureVac (5 million) and Novavax (6 million) for the population of 8.6 million people. So far, there are two vaccines approved and available in the country, those from Pfizer/BioNTech and Moderna. Johnson & Johnson’s single-dose vaccine has also been approved but has not been ordered by the Federal Office of Public Health. Others should follow.
Since January 4 (vaccinations began in late December) the government has started to roll out its vaccination planExternal link. It has set an ambitious target: to inoculate six million people or 70% of the population – on a voluntary basis – by summer, or up to 70,000 vaccine shots per day. The vaccination roll-out is being slowly scaled up. The programme has been delayed by vaccine production and delivery problems.
More
More
Coronavirus: the situation in Switzerland
This content was published on
An overview of the latest Covid-related information in the Alpine nation.
University students in Switzerland join Gaza protest wave
This content was published on
Pro-Palestinian activists occupied university buildings in Lausanne, Geneva and Zurich on Tuesday, widening the protest movement in the Alpine nation.
TradeXBank to resume full operations after Sberbank Switzerland taken off sanctions list
This content was published on
TradeXBank, the former Swiss branch of Russia’s Sberbank, will be able to resume its dollar-denominated activities from the second half of this year.
Geneva decides not to remove controversial memorials
This content was published on
The city of Geneva has presented an action plan regarding a series of controversial local statues and monuments of historical figures linked to racism, colonialism or slavery.
University of Lausanne calls for end to pro-Palestine sit-in
This content was published on
The pro-Palestinian occupation continues at the University of Lausanne (UNIL). On Monday evening, a group of students refused to agree to the deadline set by the rectorate.
Ukraine peace conference should include Russia, says Chinese ambassador
This content was published on
China supports a peace conference on the Ukraine war that would see equal participation of all parties, says Chinese Ambassador to Russia Zhang Hanhui.
This content was published on
A majority of Swiss citizens have open attitudes towards various infertility treatments, including even egg donation, which is currently prohibited.
Reports of Swiss cyber fraud almost doubled in six months
This content was published on
The head of the new Federal Office for Cybersecurity (FOC), Florian Schütz, has presented a new strategy after just over four months in office.
Data on AstraZeneca vaccine insufficient for Swiss approval
This content was published on
Swissmedic says it has not yet received enough robust data from clinical trials to give the green light to the Covid-19 vaccine.
This content was published on
Media reports indicate that vaccinating everyone who wants to by summer relies on meeting ambitious vaccine delivery targets in spring.
Covid-19 vaccine: Why we still have a long wait ahead
This content was published on
Countries have started rolling out a Covid-19 vaccine, but it will likely take years to manufacture doses at the scale needed to reach the masses.
Swiss regulator warns of fake Covid-19 vaccines online
This content was published on
Scammers are selling dangerous fake coronavirus vaccines on the internet, Switzerland’s health regulator Swissmedic warned on Tuesday.
Swiss factory rushes to prepare for Moderna Covid-19 vaccine
This content was published on
Workers are racing to set up production lines at the Lonza factory in Visp to be able to start making a vaccine for US firm Moderna later this year.
You can find an overview of ongoing debates with our journalists here . Please join us!
If you want to start a conversation about a topic raised in this article or want to report factual errors, email us at english@swissinfo.ch.